These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37717927)

  • 61. Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer.
    Wang H; Fan L; Wu X; Han Y
    BMC Womens Health; 2022 Jun; 22(1):224. PubMed ID: 35690772
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis.
    Yu Y; Zhang J; Lin Y; Kang S; Lv X; Song C
    Expert Rev Anticancer Ther; 2022 Oct; 22(10):1141-1151. PubMed ID: 36103214
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
    Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
    J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of Efficacy and Safety of Upfront Weekly Nanoparticle Albumin-bound Paclitaxel for HER2-negative Breast Cancer.
    Matsui A; Tatibana A; Suzuki N; Hirata M; Oishi Y; Hamaguchi Y; Murata Y; Nagayama A; Iwata Y; Okamoto Y
    Anticancer Res; 2017 Nov; 37(11):6481-6488. PubMed ID: 29061836
    [TBL] [Abstract][Full Text] [Related]  

  • 65. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer.
    Nahleh ZA; Barlow WE; Hayes DF; Schott AF; Gralow JR; Sikov WM; Perez EA; Chennuru S; Mirshahidi HR; Corso SW; Lew DL; Pusztai L; Livingston RB; Hortobagyi GN
    Breast Cancer Res Treat; 2016 Aug; 158(3):485-95. PubMed ID: 27393622
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer.
    Werner TL; Ray A; Lamb JG; VanBrocklin M; Hueftle K; Cohen AL; Beck AC; Buys SS; Dyess DL; Butler TW; Dumlao TL; Neumayer L; Khong HT
    Clin Breast Cancer; 2017 Nov; 17(7):503-509. PubMed ID: 28579139
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Scheduling of taxanes: a review.
    Woodward EJ; Twelves C
    Curr Clin Pharmacol; 2010 Aug; 5(3):226-31. PubMed ID: 20406166
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
    González-Martín A; Alba E; Ciruelos E; Cortés J; Llombart A; Lluch A; Andrés R; Álvarez I; Aramendía JM; de la Peña FA; Barnadas A; Batista N; Calvo L; Galve E; García-Palomo A; García-Sáenz JÁ; de la Haba J; López R; López-Vivanco G; Martínez-Jáñez N; de Dueñas EM; Plazaola A; Rodríguez-Lescure Á; Ruiz M; Sánchez-Rovira P; Santaballa A; Seguí MÁ; Tusquets I; Zamora P; Martín M
    Curr Cancer Drug Targets; 2016; 16(5):415-28. PubMed ID: 26278712
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Efficacy and Safety of Neoadjuvant Chemotherapy Containing Nanoparticle Albumin-Bound Paclitaxel (NabPTX) in Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer].
    Yoshioka S; Ota C; Moriguchi Y
    Gan To Kagaku Ryoho; 2016 May; 43(5):579-82. PubMed ID: 27210086
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers.
    Montana M; Ducros C; Verhaeghe P; Terme T; Vanelle P; Rathelot P
    J Chemother; 2011 Apr; 23(2):59-66. PubMed ID: 21571619
    [TBL] [Abstract][Full Text] [Related]  

  • 71. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer.
    Vishnu P; Roy V
    Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
    Loibl S; Jackisch C; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Wiebringhaus H; Kümmel S; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Dan Costa S; Gerber B; Engels K; Nekljudova V; von Minckwitz G; Untch M;
    Ann Oncol; 2017 Mar; 28(3):497-504. PubMed ID: 27831502
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
    Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE
    Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer.
    Mo H; Yan X; Zhao F; Teng Y; Sun X; Lv Z; Cao M; Zhao J; Song G; Pan B; Li H; Zhai J; Xu B; Ma F
    JAMA Netw Open; 2022 Nov; 5(11):e2239788. PubMed ID: 36322088
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel.
    Petrelli F; Borgonovo K; Barni S
    Expert Opin Pharmacother; 2010 Jun; 11(8):1413-32. PubMed ID: 20446855
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
    Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
    Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neoadjuvant nab-paclitaxel in the treatment of breast cancer.
    Ueno NT; Mamounas EP
    Breast Cancer Res Treat; 2016 Apr; 156(3):427-440. PubMed ID: 27072366
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records.
    Polito L; Shim J; Hurvitz SA; Dang CT; Knott A; Du Toit Y; Restuccia E; Sanglier T; Swain SM
    JCO Oncol Pract; 2023 Jul; 19(7):435-445. PubMed ID: 37167571
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Neoadjuvant chemotherapy for breast cancer with weekly nab-paclitaxel followed by epirubicin and cyclophosphamide--results of a case series.
    Hahn A; Schlotter CM; Rossmanith WG; Ulmer HU; Staiger HJ; Villena C
    In Vivo; 2014; 28(2):235-41. PubMed ID: 24632979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.